IMUNON, Inc. announced on June 3, 2025, the presentation of positive data from its Phase 2 OVATION 2 Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, with simultaneous publication in the peer-reviewed journal Gynecologic Oncology. The data showed that treatment with IMNN-001 in women with newly diagnosed advanced ovarian cancer resulted in consistent, clinically meaningful improvements across several key endpoints.
Key findings included a 13-month overall survival (OS) advantage (46 vs 33 months) over standard-of-care neoadjuvant and adjuvant chemotherapy (N/ACT) alone, based on a 31-month median follow-up. The results also demonstrated increased activity in HRD patients and those receiving PARP inhibitors, where median OS in the IMNN-001 arm had not yet been reached compared to 37.1 months in the control arm.
IMNN-001 treatment also showed a favorable safety profile, with no reports of serious immune-related adverse events. These consistent results across various participant groups, including those with BRCA1 and BRCA2 mutations, reinforce the potential of IMUNON's TheraPlas technology to transform ovarian cancer treatment. The company recently initiated the first two trial sites for its pivotal Phase 3 OVATION 3 trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.